Arbutus Biopharma (ABUS) 10-Q2022 Q1 Quarterly report

Filed: 5 May 22, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absence, accompanying, AE, AEs, affiliate, affirming, agitation, AgreementSM, Alanine, ALT, alternating, alternative, Anchor, answer, apply, arrangement, ascending, Aspatate, AST, asymptomatic, baseline, behalf, BioNTech, bona, brought, bundled, cHBV, Chinese, circumvent, COMIRNATY, complaint, compliance, Concurrent, confidence, constraint, coordinate, declaratory, deduction, deferred, Delaware, distribution, District, driven, emergent, employee, ensuing, established, evacuation, evidence, exempt, exemption, expended, exposed, fall, fasted, fed, fee, fide, GAAP, governmental, great, headache, Hong, hospital, impede, inability, incremental, infringe, infringement, infringing, injection, injunction, intact, interrupted, invasion, Investor, involvement, involving, jeopardize, knowledge, Kong, labor, laboratory, lack, lawsuit, leaving, legend, length, leveraging, licensee, listed, lost, Macau, mandate, mild, military, movement, mrna, naked, National, neuropathy, nucleic, par, partner, pay, percentage, perfected, peripheral, pertaining, Pfizer, physical, planned, prioritization, promulgated, Qilu, quality, rash, reallocation, recipient, recognition, reevaluate, relevant, restrict, restricted, Rule, ruling, Russia, science, SE, solicitation, sophistication, Southern, statistically, successful, suspended, Taiwan, Territory, thereof, thereunder, threshold, Topic, trading, transaminase, transient, Ukraine, unamortized, unconditionally, unlimited, unpredictable, USD, variable, violence, virology, visit, vital, war, warfare, withholding, worldwide, written, York

Removed: alleged, analog, arbitrator, ASU, attaching, awarding, begin, chronically, consortium, country, covered, COVID, Creating, credit, decline, degrade, demand, destabilize, duration, extreme, FASB, finite, Food, generated, greater, inclusion, infected, influence, initiate, intention, legal, lesser, member, nomination, NrtI, order, organizational, outbreak, promising, restructuring, return, scheduled, society, stay, strain, travel, twenty, ultimately, uncertainty, unpaid, Wuhan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated ABUS transcripts

ABUS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I William Collier, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.

Date: May 5, 2022


			/s/ William Collier
			Name: William Collier
			Title: President and Chief Executive Officer